Showing results (1-10 of 187) with videos related to
Sort By:
Pageof 19
The Journal of Clinical Endocrinology and Metabolism|February 26, 2009
A subnormal peak cortisol response to stimulation testing does not predict a subnormal cortisol production rateA N Paisley, S V Rowles, D Brandon, et al.Clinical Endocrinology|March 29, 2007
Withdrawal of somatostatin analogue therapy in patients with acromegaly is associated with an increased risk of acute biliary problemsA N Paisley, M E Roberts, P J TrainerEuropean Journal of Endocrinology|February 27, 2007
Pegvisomant interference in GH assays results in underestimation of GH levelsA N Paisley, K Hayden, A Ellis, et al.European Journal of Endocrinology|December 4, 2003
Insulin sensitivity and glucose tolerance improve in patients with acromegaly converted from depot octreotide to pegvisomantW M Drake, S V Rowles, M E Roberts, et al.Journal of Endocrinological Investigation|October 23, 2004
Lessons from 6 years of GH receptor antagonist therapy for acromegalyP J TrainerThe Journal of Clinical Endocrinology and Metabolism|February 25, 2011
Changes in arterial stiffness but not carotid intimal thickness in acromegalyA N Paisley, M Banerjee, M Rezai, et al.The Journal of Clinical Endocrinology and Metabolism|August 24, 2006
Reductions of circulating matrix metalloproteinase 2 and vascular endothelial growth factor levels after treatment with pegvisomant in subjects with acromegalyA N Paisley, C J O'Callaghan, K C Lewandowski, et al.Endocrinology and Metabolism Clinics of North America|September 1, 1994
Cushing's syndrome. Therapy directed at the adrenal glandsP J Trainer, M BesserGrowth Hormone & IGF Research : Official Journal of the Growth Hormone Research Society and the International IGF Research Society|September 13, 2000
Pegvisomant: a growth hormone receptor antagonist for the treatment of acromegalyC Parkinson, P J TrainerTrends in Endocrinology and Metabolism: TEM|July 1, 1990
Cushing's syndrome: difficulties in diagnosisP J Trainer, M BesserPageof 19